Literature DB >> 19107111

Deficiencies in current evaluations of the cost-effectiveness of biologic agents for RA.

Wilbert B van den Hout1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19107111     DOI： 10.1038/ncprheum0985

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN： 1745-8382


× No keyword cloud information.
  9 in total

Review 1.  What is the price of life and why doesn't it increase at the rate of inflation?

Authors:  Peter A Ubel; Richard A Hirth; Michael E Chernew; A Mark Fendrick
Journal:  Arch Intern Med       Date:  2003-07-28

2.  Cost-effectiveness analysis: out of touch with clinical reality?

Authors:  Andreas Maetzel
Journal:  Arthritis Rheum       Date:  2005-02-15

Review 3.  Work disability in rheumatic diseases.

Authors:  Edward Yelin
Journal:  Curr Opin Rheumatol       Date:  2007-03       Impact factor: 5.006

4.  It is the best of times; it is the worst of times: is there a way forward? A plethora of treatment options for rheumatoid arthritis, but critical trial design issues.

Authors:  James R O'Dell
Journal:  Arthritis Rheum       Date:  2007-12

5.  Economic evaluation of health interventions.

Authors:  Michael Drummond; Helen Weatherly; Brian Ferguson
Journal:  BMJ       Date:  2008-09-29

Review 6.  A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Authors:  Y-F Chen; P Jobanputra; P Barton; S Jowett; S Bryan; W Clark; A Fry-Smith; A Burls
Journal:  Health Technol Assess       Date:  2006-11       Impact factor: 4.014

7.  Contemporary prevalence and incidence of work disability associated with rheumatoid arthritis in the US.

Authors:  Saralynn Allaire; Frederick Wolfe; Jingbo Niu; Michael P Lavalley
Journal:  Arthritis Rheum       Date:  2008-04-15

Review 8.  The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review.

Authors:  Mark J Harrison; Linda M Davies; Nick J Bansback; Mary Ingram; Aslam H Anis; Deborah P M Symmons
Journal:  J Rheumatol       Date:  2008-02-15       Impact factor: 4.666

9.  Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis.

Authors:  Wilbert B van den Hout; Yvonne P M Goekoop-Ruiterman; Cornelia F Allaart; Jeska K de Vries-Bouwstra; J Mieke M Hazes; Pit J S M Kerstens; Derkjen van Zeben; Harry M J Hulsmans; Johanna M de Jonge-Bok; Peter B J de Sonnaville; Ben A C Dijkmans; Ferdinand C Breedveld
Journal:  Arthritis Rheum       Date:  2009-03-15
  9 in total
  1 in total

1.  Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china.

Authors:  Bin Wu; Alisa Wilson; Fang-fang Wang; Su-li Wang; Daniel J Wallace; Michael H Weisman; Liang-jing Lu
Journal:  PLoS One       Date:  2012-10-09       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.